| dbo:abstract |
موتافيزوماب هو جسم مضاد وحيد النسيلة مأنسن طورته (تتبع حالياً) لمنع عدوى فيروس الجهاز التنفسي المخلوي في الرضع المعرضين لخطر مرتفع الشدة. (ar) Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials. In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab. In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV. (en) |
| dbo:alternativeName |
Numax (en) |
| dbo:casNumber |
677010-34-3 |
| dbo:drugbank |
DB06310 |
| dbo:fdaUniiCode |
50Y163LK8Q |
| dbo:kegg |
D06621 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/motavizumab |
| dbo:wikiPageID |
9680191 (xsd:integer) |
| dbo:wikiPageLength |
3694 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1124006939 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Respiratory_syncytial_virus dbr:Infant dbc:Experimental_drugs dbr:MedImmune dbr:Clinical_trials dbr:Food_and_Drug_Administration dbc:AstraZeneca_brands dbr:International_Nonproprietary_Name dbr:AstraZeneca dbr:Humanized_monoclonal_antibody dbr:Intravenous |
| dbp:atcPrefix |
J06 (en) |
| dbp:atcSuffix |
BD02 (en) |
| dbp:c |
6476 (xsd:integer) |
| dbp:casNumber |
677010 (xsd:integer) |
| dbp:chemspiderid |
none (en) |
| dbp:drugbank |
DB06310 (en) |
| dbp:h |
10014 (xsd:integer) |
| dbp:kegg |
D06621 (en) |
| dbp:mabType |
mab (en) |
| dbp:n |
1706 (xsd:integer) |
| dbp:o |
2008 (xsd:integer) |
| dbp:proteinBound |
None (en) |
| dbp:routesOfAdministration |
dbr:Intravenous |
| dbp:s |
48 (xsd:integer) |
| dbp:source |
zu/o (en) |
| dbp:target |
RSV glycoprotein F (en) |
| dbp:tradename |
Numax (en) |
| dbp:type |
mab (en) |
| dbp:unii |
50 (xsd:integer) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
458284116 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:wikiPageUsesTemplate |
dbt:As_of dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:AstraZeneca dbt:Immune_sera_and_immunoglobulins dbt:Monoclonals_for_infectious_disease_and_toxins dbt:Antiinfective-drug-stub dbt:Monoclonal-antibody-stub |
| dcterms:subject |
dbc:Experimental_drugs dbc:AstraZeneca_brands |
| gold:hypernym |
dbr:Antibody |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug umbel-rc:DrugProduct |
| rdfs:comment |
موتافيزوماب هو جسم مضاد وحيد النسيلة مأنسن طورته (تتبع حالياً) لمنع عدوى فيروس الجهاز التنفسي المخلوي في الرضع المعرضين لخطر مرتفع الشدة. (ar) Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials. (en) |
| rdfs:label |
موتافيزوماب (ar) Motavizumab (en) |
| owl:sameAs |
freebase:Motavizumab yago-res:Motavizumab wikidata:Motavizumab dbpedia-ar:Motavizumab dbpedia-vi:Motavizumab https://global.dbpedia.org/id/4ry5s |
| prov:wasDerivedFrom |
wikipedia-en:Motavizumab?oldid=1124006939&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Motavizumab |
| is dbo:wikiPageRedirects of |
dbr:Numax dbr:ATC_code_J06BB17 dbr:Motovizumab |
| is dbo:wikiPageWikiLink of |
dbr:Respiratory_syncytial_virus dbr:Numax dbr:ATC_code_J06BB17 dbr:ATC_code_J06 dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Mo dbr:List_of_drugs:_Nj–Nz dbr:Motovizumab |
| is foaf:primaryTopic of |
wikipedia-en:Motavizumab |